Table 1.

People who have anti-HBs titre after completion of primary vaccine series less than 10 mIU/mL

	Celiac patients (no responders, %)	Control subjects (no responders, %)
Leonardi et al[30]	30/60 (50)	7/60 (11.7)
Ahishali et al[42]	8/25 (32)	0/20 (0)
Zingone et al[43]	31/51 (60.7)	13/48 (27.08)
Ertekin et al[44]	20/52 (38.5)	2/20 (10)
Noh et al[56]	13/19 (68.4)	-